Biogen takes aim at Alzheimer's, ALS drugs

Facebook
VKontakte
share_fav

Biogen has seen its value quadruple to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions.

view CNBC: US News